Five Prime Therapeutics Advances FPA008 Into Phase 2 Dose Expansion in Patients with Pigmented Villonodular Synovitis (PVNS)
May 12, 2016 09:00 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 12, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) a clinical-stage biotechnology company focused on discovering and developing novel protein...
Five Prime Therapeutics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
May 06, 2016 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 06, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Announces First Quarter 2016 Results and Provides Business Update
May 05, 2016 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics to Announce First Quarter 2016 Financial Results and Host Conference Call on May 5
April 21, 2016 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics Announces New Pre-Clinical Data on FPA144 Presented at the 2016 AACR Annual Meeting
April 18, 2016 09:00 ET
|
Five Prime Therapeutics, Inc.
Engineering of FPA144 for ADCC drives both innate and adaptive responses Recruitment of Natural Killer (NK) and T cells into the tumor and regression of tumor growth in vivo FPA144 may...
Five Prime Therapeutics Announces FPA144 Will Be Featured During a Special Session at the 2016 AACR Annual Meeting
April 11, 2016 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 11, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics to Present at the 2016 Jefferies Immuno-Oncology Summit
April 01, 2016 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 01, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and...
Five Prime Therapeutics to Present New Pre-Clinical Data on FPA144 at the 2016 AACR Annual Meeting
March 16, 2016 16:30 ET
|
Five Prime Therapeutics, Inc.
Enhanced ADCC activity of FPA144 may play an important mechanistic role in anti-tumor efficacy in cancers with modest expression of FGFR2b.FPA144 may reprogram the tumor micro-environment to create...
Five Prime Therapeutics Announces Changes to Board of Directors
March 16, 2016 09:00 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 16, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics to Present at the Barclays Global Healthcare Conference
March 11, 2016 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 11, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and...